Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Research article

Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

Emanuele Focà1, Davide Motta1, Marco Borderi2, Daria Gotti1, Laura Albini1, Alessandra Calabresi1, Ilaria Izzo1, Rita Bellagamba3, Pasquale Narciso3, Laura Sighinolfi4, Alberto Clò5, Davide Gibellini5, Eugenia Quiros-Roldan1, Nigritella Brianese1, Bruno Mario Cesana6, Maria Carla Re5 and Carlo Torti17*

Author Affiliations

1 Infectious Diseases Department, University of Brescia, Brescia, Italy

2 Infectious Diseases Section, University of Bologna, Bologna, Italy

3 National Institute of Infectious Diseases, Rome, Italy

4 Infectious Diseases Department, S. Anna Hospital, Ferrara, Italy

5 Microbiology Section, University of Bologna, Bologna, Italy

6 Medical Statistics and Biometry Section, University of Brescia, Brescia, Italy

7 Institute of Infectious and Tropical Diseases, University of Brescia, School of Medicine, P.le Spedali Civili, 1, 25123 Brescia, Italy

For all author emails, please log on.

BMC Infectious Diseases 2012, 12:38  doi:10.1186/1471-2334-12-38

Published: 14 February 2012

Abstract

Background

Increased risk of fractures and osteoporosis have been associated with the use of antiretroviral drugs. There is a paucity of prospective evaluations of bone markers after the initiation of drugs currently recommended to treat HIV infection and results on the evolution of these markers are conflicting. Lastly, the effect of tenofovir on 1,25-(OH)2 vitamin D is uncertain.

Methods

We performed a prospective study on the evolution of bone markers, parathormone and 1,25-(OH)2 vitamin D before and after standard antiretroviral regimens. This was a sub-study of a trial conducted in antiretroviral-naïve patients randomized to tenofovir + emtricitabine in combination with either atazanavir/ritonavir (ATV/r) or efavirenz (EFV). Follow-up lasted 48 weeks. The following bone markers were analyzed: C-terminal cross-laps (CTx), osteocalcin (OC), osteoprotegerin (OPG), and receptor activator of nuclear factor κB ligand (RANKL). Mixed-factorial analysis of variance with random-coefficient general linear model was used to compare their trends over time and linear multivariable regression was performed with a backward selection method to assess predictors of their variations from baseline to week 48. Trends of parathormone and 1,25-(OH)2 vitamin D were also evaluated.

Results

Seventy-five patients were studied: 33 received EFV and 42 ATV/r. Significant increases were found for all markers except for RANKL. There was a significant direct association between CTx and OC increases. Multivariable analysis showed that higher glomerular filtration rate (estimated through cystatin C clearance) predicted greater OPG increase, while older age, higher HIV RNA at baseline and use of ATV/r predicted greater CTx increase. A significant increase of parathormone accompanied the evolution of the study markers. 1,25-(OH)2 vitamin D remained stable, though a seasonality variation was demonstrated.

Conclusions

These data demonstrate CTx increase (bone resorption marker) corresponding to OC increase (bone formation marker) early upon HAART initiation. Moreover, predictors of bone marker increases have been suggested, possibly indicating that a stricter monitoring of bone health and pro-active interventions are needed in older patients, those with higher HIV RNA, prescribed ATV/r rather than EFV, and with decreased renal function at baseline. Further studies are needed to clarify the mechanisms responsible for up-regulation of bone turnover markers, as well as to understand if and what markers are best correlated or predictive of pathological fractures.

Keywords:
HIV; Antiretroviral therapy; Bone turnover; Osteoporosis; Vitamin D